Recent Publications by Celgene Corporation: |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Lenalidomide (Revlimid(R)) is approved for the treatment of... | 23rd September, 2008
| Department of Immunotherapeutics, Celgene Corporation, 86 Morris Avenue,
| Microvasc Res. 2008 Sep 4.
DOI Direct Link |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
PURPOSE: Lenalidomide has significant activity in myelodysplastic... | 17th September, 2008
| Celgene Corporation, Summit, New Jersey 07901, USA.
| Clin Cancer Res. 2008 Jul 15;14(14):4650-7.
DOI Direct Link |
CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet.
The IMiDs immunomodulatory drugs are an expanding family of compounds... | 6th September, 2008
| Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA.
| Clin Immunol. 2008 Sep;128(3):392-9. Epub 2008 Jun 20.
DOI Direct Link |
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Uveal melanoma metastases occur most commonly in the liver. Given the 50%... | 30th August, 2008
| Multidisciplinary Oncology Center, University of Lausanne Hospitals
| Melanoma Res. 2008 Jun;18(3):220-4.
DOI Direct Link |
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide.
Lenalidomide (Revlimid) is an immunomodulatory drug and an analogue of... | 19th August, 2008
| Global Drug Safety, Celgene Corporation, Summit, New Jersey 07901, USA.
| Drug Saf. 2008;31(9):743-52.
|
The content of their character.
PURPOSE: Lenalidomide has significant activity in myelodysplastic... | 23rd July, 2008
| Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
| Ann Intern Med. 2008 Jul 15;149(2):142-3.
|
Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.
Uveal melanoma is associated with a high mortality rate once metastases... | 19th July, 2008
| Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire
| Int J Cancer. 2008 Sep 1;123(5):1215-8.
DOI Direct Link |
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
PURPOSE: The major cause of death in aggressive lymphoma is relapse or... | 9th July, 2008
| Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY;
| J Clin Oncol. 2008 Jul 7.
DOI Direct Link |
Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds.
We generated the organic anion transporting polypeptide (Oatp) 1b2... | 17th June, 2008
| Drug Metabolism and Pharmacokinetics, Celgene Corporation, San Francisco,
| Drug Metab Dispos. 2008 Sep;36(9):1840-5. Epub 2008 Jun 12.
DOI Direct Link |
Simultaneous determination of cations, zwitterions and neutral compounds using mixed-mode reversed-phase and cation-exchange high-performance liquid chromatography.
A novel mixed-mode reversed-phase and cation-exchange high-performance... | 31st May, 2008
| Analytical Research and Development, Celgene Corporation, Summit, NJ
| J Chromatogr A. 2008 Mar 28;1185(2):185-93. Epub 2008 Feb 12.
DOI Direct Link |
An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.
Revlimid((R)) (Lenalidomide, CC-5013) and CC-4047 are IMiDs((R))... | 9th May, 2008
| Multidisciplinary Oncology Center, University of Lausanne Hospitals
| Cancer Immun. 2008 Mar 27;8:6.
|
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public... | 15th April, 2008
| Celgene Corporation,
| J Clin Invest. 2008 Jan;118(1):248-58.
DOI Direct Link |
Immunomodulatory drugs Revlimid((R)) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Revlimid((R)) (Lenalidomide, CC-5013) and CC-4047 are IMiDs((R))... | 9th April, 2008
| Celgene Corporation, 4550 Towne Centre Court, San Diego, CA, 92121, USA,
| Cancer Immunol Immunother. 2008 Dec;57(12):1849-59. Epub 2008 Apr 8.
DOI Direct Link |
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
The present study investigated the effect of renal impairment and... | 4th March, 2008
| Celgene Corporation, 86 Morris Avenue, Summit, NJ 07091, USA.
| J Clin Pharmacol. 2007 Dec;47(12):1466-75. Epub 2007 Oct 22.
DOI Direct Link |
[Molecular targeting therapy for multiple myeloma]
Molecular target therapy is the most progressive and promising anticancer... | 22nd February, 2008
| Clinical Development, Celgene KK.
| Nippon Rinsho. 2007 Dec;65(12):2345-50.
|
